Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.
about
Dysregulated metabolism contributes to oncogenesisOverview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial FluidImproving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imagingSubharmonic aided pressure estimation for monitoring interstitial fluid pressure in tumours--in vitro and in vivo proof of conceptRadionuclide I-131 Labeled Albumin-Paclitaxel Nanoparticles for Synergistic Combined Chemo-radioisotope Therapy of Cancer.Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results.Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenationInterstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumoursNovel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice.A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptakePhase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer.Understanding Drug Resistance in Breast Cancer with Mathematical OncologyModulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor modelsPenetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.Cancer drug delivery: considerations in the rational design of nanosized bioconjugates.Optical tomography with ultrasound localization: initial clinical results and technical challenges.Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.Neoadjuvant treatment in rectal cancer: actual status.Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumabNaive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.The current state of targeted agents in rectal cancer.Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report.Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting.Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy.Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics.Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis.The effects of mechanical forces on intestinal physiology and pathology.Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.Transport properties of pancreatic cancer describe gemcitabine delivery and responseEpothilones in the treatment of ovarian cancer.Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents.Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?Intratumor heterogeneity and its impact on drug distribution and sensitivity.
P2860
Q26784630-11E45FFA-0CA2-420E-90C0-12A4428FC094Q26799981-E9834E10-54ED-47E1-9EFF-A863E5B82134Q26999332-C0E12315-F100-4EFE-A5D7-3F0D67025C7EQ28535605-D87A7B93-189E-4735-B241-D8451549C23AQ30404198-B9163199-D164-47F5-A06E-E18142F9A544Q30840017-48EC721F-148D-41CA-A3AB-428C034D7743Q31092479-ABA71CC9-2002-449C-99CE-55000EBD2FE0Q33258552-A3890A4C-EE8C-4AD4-B9ED-5D573457C04DQ33313523-1F133D77-9464-4CC5-AC95-523354DEAD1CQ33624697-2236AD46-EE0F-4FE7-AC42-AD9AE60C6748Q33639027-D68C24AB-A48A-48CB-B026-5F5DE2DEA1B7Q33686177-112F286C-6CE6-4707-8A25-8F25672242CFQ33690336-53EFBF35-1E5C-43B3-9C2D-1DBC71FEAC73Q33733303-F2510277-3EA8-4204-A9E3-3F4CB90EE2BEQ33879424-329B8051-D78D-4077-AC02-C7CF54AC6463Q34294361-FE568519-5787-462F-8182-01D7C3FEA51AQ34433040-1B9F37E0-E86E-439A-8B42-F6973C18A0A9Q34764424-3615A21A-8525-41AD-A57C-93E926FFB77FQ34943898-7522210A-9357-4CB5-B7E6-BCD514894EECQ35152357-5B2CB122-8072-4C6E-A2F8-C896768D8600Q35675494-2AA0E375-3D7B-4E72-AE49-E9D414029BB3Q35687452-C8A68480-4AD1-4213-A21A-59A9F72ED099Q35842769-5DAA7FBF-E315-482A-A566-BB4A119C0770Q35914472-D41181CC-D585-40F1-A256-40BA38F76745Q35996651-BED6C917-70AC-42CA-91A7-E0A080AD3508Q36218165-2560FC34-5C5A-4437-B82D-F36C3947C35DQ36390229-CEF5D415-98E6-4068-B755-7F3CE4C23B2CQ36424359-6CB0B335-35EF-436A-ADA5-52E550C34AA0Q36757056-F986C6EC-5CFC-4372-9AD1-ADA6C6B71519Q36807138-1640EF84-954D-45B7-9160-1742A5691887Q37238130-713741AB-6A41-4264-8D09-7C51CCE104B4Q37328101-521C63DD-34C2-4116-85F0-D60F3501A046Q37352000-0338675C-1013-4F77-AD13-E651A4C54634Q37403172-C9B4F54A-7E00-48AB-9165-4900EC0CB751Q37461422-ADCD5233-77D3-4912-B5BF-8C3D07079D93Q37679971-6A11EA3F-C159-433B-9EC4-70F9B3F3AB8BQ37861204-960ACD1E-4387-46AB-BBD0-6B6655100C19Q38150356-AA80BC07-2FAB-4B69-8D74-5094CE2316FDQ38195674-5A4C1406-A5DB-4E62-BACB-7CC8492DDD74Q38211694-58412EB4-05D5-4D34-A8E5-03BFDDF821AD
P2860
Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Paclitaxel decreases the inter ...... herapy: clinical implications.
@ast
Paclitaxel decreases the inter ...... herapy: clinical implications.
@en
type
label
Paclitaxel decreases the inter ...... herapy: clinical implications.
@ast
Paclitaxel decreases the inter ...... herapy: clinical implications.
@en
prefLabel
Paclitaxel decreases the inter ...... herapy: clinical implications.
@ast
Paclitaxel decreases the inter ...... herapy: clinical implications.
@en
P2093
P356
P1476
Paclitaxel decreases the inter ...... herapy: clinical implications.
@en
P2093
Adrian Casty
Alphonse G Taghian
Irene Kuter
Khaled Attia
Marek Ancukiewicz
Peryhan Molokhia
Rita Abi-Raad
Sherif I Assaad
Simon N Powell
P304
P356
10.1200/JCO.2005.08.119
P407
P577
2005-03-01T00:00:00Z